Report overview
Ischemic heart disease (IHD), refers to a group of diseases which includes stable angina, unstable angina, myocardial infarction, and sudden cardiac death. It is within the group of cardiovascular diseases of which it is the most common type. A common symptom is chest pain or discomfort which may travel into the shoulder, arm, back, neck, or jaw.
This report aims to provide a comprehensive presentation of the global market for Ischemic Heart Disease (IHD)Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ischemic Heart Disease (IHD)Drugs. This report contains market size and forecasts of Ischemic Heart Disease (IHD)Drugs in global, including the following market information:
Global Ischemic Heart Disease (IHD)Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Ischemic Heart Disease (IHD)Drugs Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Ischemic Heart Disease (IHD)Drugs companies in 2022 (%)
The global Ischemic Heart Disease (IHD)Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Ways to reduce CAD risk include eating a healthy diet, regularly exercising, maintaining a healthy weight, and not smoking. Medications for diabetes, high cholesterol, or high blood pressure are sometimes used. Additional medications such as antiplatelets, beta blockers, or nitroglycerin may be recommended.
We surveyed the Ischemic Heart Disease (IHD)Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Ischemic Heart Disease (IHD)Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Ischemic Heart Disease (IHD)Drugs Market Segment Percentages, by Type, 2022 (%)
Antidyslipidemic Drugs
Calcium Channel Blockers
Beta-blockers
ACE Inhibitors
Vasodilators
Antithrombotic Agents
Others
Global Ischemic Heart Disease (IHD)Drugs Market, by Sales Channel, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Ischemic Heart Disease (IHD)Drugs Market Segment Percentages, by Sales Channel, 2022 (%)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Global Ischemic Heart Disease (IHD)Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Ischemic Heart Disease (IHD)Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Ischemic Heart Disease (IHD)Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Ischemic Heart Disease (IHD)Drugs revenues share in global market, 2022 (%)
Key companies Ischemic Heart Disease (IHD)Drugs sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Ischemic Heart Disease (IHD)Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
AstraZeneca
Bayer
Eli Lilly
Novartis
Pfizer
Sanofi
Outline of Major Chapters:
Chapter 1: Introduces the definition of Ischemic Heart Disease (IHD)Drugs, market overview.
Chapter 2: Global Ischemic Heart Disease (IHD)Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Ischemic Heart Disease (IHD)Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by sales channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Ischemic Heart Disease (IHD)Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Ischemic Heart Disease (IHD)Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
